Regenerative Medicine Market Research Report—Global Forecast till 2027

Regenerative Medicine Market: Information by Type (Cell Therapy, Gene Therapy, Tissue Engineering, Small Molecule & Biologic), by Material (Synthetic, Genetically Engineered, Biologically Derived), by Application (Musculoskeletal Disorders, Wound Care, Oncology,Ocular Disorders,Diabetes), by End User (Hospitals, Specialty Centers, Academic & Research Institutes), and Region (Americas, Europe, Asia-Pacific, and Middle East & Africa)—Forecast till 2027

ID: MRFR/HC/1649-CR | August 2021 | Region: Global | 171 pages

Regenerative Medicine Market Forecast


The regenerative medicine market is expected to reach USD 152,501.51 million by 2027 at a CAGR of 21.18%.  


Market Overview:


The global regenerative medicine market is growing steadily. Factors that influence the regenerative medicine market are increasing advancement in healthcare technology, advanced technology in the regenerative medicine market, increasing prevalence of chronic diseases, and increasing growth in stem cell technology. Globally the market for regenerative medicine is expected to grow at the rate of about 21.18% from 2021 to 2027.


COVID-19 Analysis:


The rising prevalence of COVID-19 is projected to influence market growth over the forecast period.Like most of the markets, COVID-19 has also affected the regenerative medicine market and the market players.COVID-19 has decelerated the drug development process, resulting in slashed financing by the investors. Thus, the COVID-19 has restricted the growth of the market players. Similarly, the impact of COVID-19 on the R&D of regenerative medicines is unfavorable. The worst-hit entities are the clinics that are meant to perform clinical trials. The results of these clinical trials hold great importance to the involved regenerative medicine experts and investors. Most of the clinical trials have their enrolment postponed dealing with the rising number of COVID-19 patients and keeping the already enrolled participants away from contracting COVID-19. This has brought the initiation of new clinical trials to a standstill. Moreover, the participants skipped the clinical trials owing to the factors such as fear of contracting COVID-19, travel restrictions, etc. As a result, it can be said that COVID-19 has a negative impact on R&D.


Market Dynamics:


Market Drivers



  • Increasingprevalence of chronic diseases and genetic disorders


According to the Centre for Diseases Control and Prevention in 2019, the prevalence of chronic diseases in adults was around 60% globally, and it is reportedly much higher among elderly people. It is estimated that about 70% of adults will die of one or more chronic diseases. It is reported that 84.1 million people in the US were diagnosed with prediabetes in 2019. Similarly, according to a case study by the Royal Society in 2017, the oldest scientific academy in continuous existence, over half a million people in the United Kingdom were diagnosed with a genetic disorder. Thus, the Increasing prevalence of chronic diseases and genetic disorders drives thegrowth of the globalregenerative medicine market



  • Growing adoption of stem cell technology

  • Rising number of approvals and product launches


Market Restraints



  • Ethical concerns for the use of embryonic stem cells


ethical concernsfor the use of embryonic stem cells are, including well-informed consent from the embryo donating woman or pair, consent from the donors of the gamete involved in the embryo creation, and the confidentiality of donor details. Thus, the ethical concerns for using embryonic stem cells are expected to restrict the growth of the global regenerative medicine market to a certain extent during the forecast period.


Market Opportunities



  • Implicit guidelines by the international society for stem cell research (ISSCR) related to the extended embryo culture


In May 2021, the International Society for Stem Cell Research (ISSCR), the world's largest stem cell body, implicitly talked about the willingness to reassess the long-established restriction on laboratory efforts to cultivate and examine human embryos. Under the latest guidelines, the ISSCR also focuses upon a probable substitute for using human embryos;these guidelines may not be laws, the ISSCR might be able to fuel the discussion considering its soft power and the influence it has on the stem cell research community. These new guidelines have implicitly allowed more permissive research on human embryos. These guidelines are expected to create growth opportunities for the key entities operating in the global regenerative medicine market.


Global Regenerative Medicine Market Share (%), byType, 2020
Regenerative Medicine Market Share by Type 2020
Source: MRFR Analysis


Value Chain Analysis


The global regenerative medicine market is growing rapidly and is expected to continue growing at a steady during the study period. This is due to the growing contribution of existing players to make the product more effective. The supply chain analysis for the regenerative medicine market comprises four major components, which start with the research and product development followed by manufacturing of the products, distribution&sales, and ends with post-sales services.


The key market players focus onthe introduction of new products to strengthen their position in the market.For instance, in February 2020,Integra Lifesciences Holding Corporation launched AmnioExcel Plus Placental Allograft Membrane,a wound care offering to support soft tissue repair.


Segment Overview


The global regenerative medicine market has been divided based ontype,material,application, and end user.


By Type



  • Cell Therapy


Cell therapy is the transplantation of healthy cells to repair or replace damaged cells or tissues. With the latest advancements in technologies and innovation in products, a variety of cells, such as hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), skeletal muscle stem cells, dendritic cells, lymphocytes, and pancreatic islet cells, just to name a few, can be used as a part of treatment or therapy for a range of chronic diseases and disorders.



  • Gene Therapy


Gene therapy entails the altering of genes within the patient's cells to cure or stop the disease. Our genes consist of our DNA which is basically the molecule that carries our genetic code, the code that controls much of our body's function and form. Faulty genes can cause one or more diseases. Gene therapy is used to replace faulty genes or add new ones to treat disease or enhance our body's ability to fight disease.



  • Tissue Engineering


Tissue engineering involves the fabrication of bioartificial tissues in vitro and the in vitro alteration of cell development and function by means of transplantation of suitable cells isolated from the tissues of the donor and scaffolds. The aim of tissue engineering is to put together functioning constructs that restore, nurture, or help improve damaged tissues or entire organs.



  • Small Molecule & Biologic


Small molecule drugs can be described as organic compounds with low molecular weight which can be produced by chemical synthesis. They can be administered by different kinds of routes, including orally. On the other hand, biologics include various products such as blood and blood components, somatic cells, vaccines, allergenic, tissues, gene therapy, and recombinant therapeutic proteins. 


By Material


On the basis of material, the market is bifurcated intosynthetic, genetically engineered, biologically derived, and others.The biologically derived segment accounted for the larger market share and is anticipated to register a CAGR of 21.39% from 2021 to 2027.



  • Synthetic


The biomaterials used in synthetic regenerative medicines include both degradable polymers and non-degradable materials.With the advancements in bioengineering, the synthetic regenerative medicine market is expected to grow during the forecast period.



  • Genetically Engineered


Human mesenchymal stem cells (hMSCs) and human embryonic stem cell-derived cells (hESdCs) are the mainstays of the genetically engineered regenerative medicine market. These offer great potential and could offer superior treatments/therapies for chronic diseases and genetic disorders.



  • Biologically Derived


Biologically derived polymeric scaffolds are used as a temporary extracellular matrix (ECM) in regenerative medicine and tissue engineering. The biologically active biomaterials and scaffolds are derived through the physical adsorption of the biomolecules lying on scaffold surface, physical capture of the biomolecules in hydrogels or polymer microspheres, and enzymatic immobilization of proteins on biomaterials or oligopeptides.



  • Others


Others include umbilical cord blood (CB) and organ-on-chip (OOC)


By Application


On the basis of application, musculoskeletal disorders, wound care, oncology, ocular disorders, diabetes, and others.The oncology segment accounts for the larger market share and is projected to reach USD 52,481.78 million by the end of 2027,owing to the factors such as the rising product pipeline of regenerative medicine and advancements in regenerative medicine research.



  • Musculoskeletal Disorders


Musculoskeletal disorders are disorders or injuries of the muscles, tendons, nerves, cartilage, joints, and spinal discs.



  • Wound Care


When it comes to wound healing, regenerative medicines have been seen as a modern alternative to traditional treatments available for wound care. These regenerative medicines have great potential as their capability to regenerate, replace, and rejuvenate action can work in tandem with the body's own natural wound care processes towards promoting healing and recovery in various cases, including chronic wound treatment, aging skin repair, pain management, skin transplants, and organ transplants.



  • Oncology


The regenerative medicine companies, with the help of leading oncologists around the world, have been trying to develop treatments that can cure cancer.According to Alliance for Regenerative Medicine, as of June 2019, globally, over 400 companies were developing regenerative medicine therapies that can cure cancer, with 191 of them being clinical stage. With 23 of 627 ongoing clinical trials in Phase III, over 132 products were in active development in June 2019.



  • Ocular disorders


Ocular disorders primary includes age-related macular degeneration (AMD), diabetic retinopathy, amblyopia, glaucoma, strabismus, and cataract. These disorders are the leading causes of low vision and blindness. The regenerative medicine companies have been working on ocular regenerative therapies to transform the existing treatments for ocular disorders.



  • Diabetes


The World Health Organization (WHO) describes diabetes as a chronic metabolic disease identified by elevated blood glucose (or blood sugar) levels. Elevated blood glucose levels lead to severe health problems over time, including serious damage to the blood vessels, nerves, heart, kidneys, and eyes. The number of diabetes cases has been rising worldwide at an alarming rate.



  • Others


Others include bladder reconstruction, blood vessels (vascular grafts), trachea, eyes, and others.


By End User


On the basis of end user, the market is bifurcated intohospitals, specialty centers, academic & research institutes, and others. The hospitals segment accounted for the larger market share with a value of USD 23,617.00 million in 2020; sinceadvanced treatment procedures are available in hospitals, patients usually prefer to be treated in hospitals.



  • Hospitals


Hospitals are the primary locations for patients receiving consulting & treatment. Since advanced treatment procedures are available in hospitals, patients usually prefer to be treated in hospitals. Moreover, the presence of many hospitals is likely to support market growth. For instance, the US has about 6,090 active hospitals, and a well-established healthcare sector will boost the growth of the market during the forecast period.



  • Specialty Centers


With the arrival of stem cell technology, the healthcare system witnessed a paradigm shift from fighting disease to restoring health. In order to establish the regulated regenerative therapies for the patients, specialized teams are being educated to guarantee valid and safe regenerative options.



  • Academic and Research Institutes


Academic and research institutes are primarily responsible for the advancements in the regenerative medicine industry today. With the help of monetary resources coming from corporate partnerships, private placements, and venture financing, these institutes have researched and developed methods to treat chronic diseases and genetic disorders. In the regenerative medicine ecosystem, academic and research institutes are of utmost importance.



  • Others


Others include pathology labs and biotechnology companies


Global Regenerative Medicine Market Share (%), by Region, 2020
Regenerative Medicine Market Share by Region 2020
Source: MRFR Analysis


Regional Analysis


The global regenerative medicine market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa.


Americas:


The Americas is expected to command the largest market share due to the rising number of clinical trials, enactment of the 21st Century Cures Act, increasing monetary support by investors, favorable government policies, and establishment of institutions such as the American Academy of Regenerative Medicine (AARM) and the American Board of Regenerative Medicine (ABRM), for setting regulatory standards and promoting excellence in the area of regenerative medicine.


Europe:


Europe also accounted for a significant market share owing to the success of the pan-European projects (such as CHRODIS and CHRODIS PLUS), government initiatives, public and private research funders, and collaborative scientific research projects in the field of regenerative medicine. According to a case study by the Royal Society in 2017, the oldest scientific academy in continuous existence, over half a million people in the UK were diagnosed with some kind of genetic disorder. For instance, the number of people suffering from cystic fibrosis in Scotland is almost twice the global average.


Asia-Pacific:


Asia-Pacific is estimated to be significant in regenerative medicine treatment due to transformation in healthcare infrastructure, cross-country scientific research programs, and training of researchers and young faculties at leading institutes in the field of tissue engineering and stem cell-based research. The Department of Biotechnology under the Ministry of Science and Technology, Government of India, implemented a joint Indo-Japan collaborative research program to major disorders related to brain and blood among the Indian population through a combined approach of clinical investigations, modern advancements in human genetics, and stem cell technology


Middle East & Africa:


The Middle East & Africa accounts for the minimum share of the regenerative medicine market due to regional political tensions, which have led to limited investments in the field of regenerative medicine across the region.


Competitive Landscape


The global regenerative medicine market is expected to grow significantly in the coming years due to the increasing prevalence of chronic diseases and genetic disorders, growing adoption of stem cell technology, and rising product pipeline of regenerative medicine. The global regenerative medicine market is characterized by the presence of several global and regional vendors. The market is highly competitive, with all the players trying to gain maximum market share. For instance, in February 2020, Integra Lifesciences Holding Corporation launched AmnioExcel Plus Placental Allograft Membrane. It is a wound care offering to support soft tissue repair.


List of Key Companies Covered in this report:



  • Zimmer Biomet Holdings Inc. (US)

  • AbbVie Inc. (US)

  • Cryolife, Inc. (US)

  • Stryker (US)

  • Medtronic Plc (Ireland)

  • Baxter International Inc. (US)

  • Organogenesis Inc. (US)

  • Ocata Therapeutics Inc. (US)

  • Integra Lifesciences Holdings Corporation (US)

  • Vericel Corporation (US)

  • Reliance Life Sciences (India)


Recent Developments



  • In May 2020, AbbVie Inc. completed the acquisition of Allergan plc. Allergan is developing and manufacturing branded pharmaceutical devices and biologic, surgical, and regenerative medicine products.

  • In May 2017, Vericel Corporationreceived FDA regenerative medicine advanced therapy (RMAT) designation for Ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.


Report Overview:


The study covers the existing short-term and long-term market effects, helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The report analyzes market drivers, restraints, opportunities, challenges, Porter's Five Forces, Value Chain, and impact of COVID-19 on the market.


Scope of the Report & Segmentation


Global Regenerative Medicine Market, byType



  • Cell Therapy

  • Gene Therapy

  • Tissue Engineering

  • Small Molecule & Biologic


Global Regenerative Medicine market, byMaterial



  • Synthetic

  • Genetically Engineered

  • Biologically Derived

  • Others


Global Regenerative Medicine market, by Application



  • Musculoskeletal Disorders

  • Wound Care

  • Oncology

  • Ocular Disorders

  • Diabetes

  • Others


Global Regenerative Medicine Market, by End User



  • Hospitals

  • Specialty Centers

  • Academic and Research Institutes

  • Others


Global Regenerative Medicine market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America



  • Europe

    • Western Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe

    • Eastern Europe



  • Asia-Pacific

    • China

    • India

    • Japan

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • Middle East & Africa

    • Middle East

    • Africa





Report Scope:
Report Attribute/Metric Details
  Market Size   2027: USD 152,501.51 Million
  CAGR   21.18%
  Base Year   2020
  Forecast Period   2021-2027
  Historical Data   2017 to 2019
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Material, Application, End User, and Region
  Geographies Covered   Americas, Europe, Asia-Pacific,Middle East & Africa
  Key Vendors   • Zimmer Biomet Holdings Inc. (US) • AbbVie Inc. (US) • Cryolife, Inc. (US) • Stryker (US) • Medtronic Plc (Ireland) • Baxter International Inc. (US) • Organogenesis Inc. (US) • Ocata Therapeutics Inc. (US) • Integra Lifesciences Holdings Corporation (US) • Vericel Corporation (US) • Reliance Life Sciences (India)
  Key Market Opportunities   • Implicit guidelines by the international society for stem cell research (ISSCR) related to the extended embryo culture
  Key Market Drivers   • Increasing prevalence of chronic diseases and genetic disorders • Growing adoption of stem cell technology • Rising number of approvals and product launches


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


The global regenerative medicine market is projected grow at approximately 25.5% CAGR during the assessment period (2020-2027).

Increasing incidences of degenerative diseases and shortage of organs for transplantation and increasing utilization of nanomaterials in wound care, drug delivery, and immunomodulation are the major tailwinds pushing the growth of the global regenerative medicine market.

North America holds the largest share in the global regenerative medicine market, followed by Europe and the Asia Pacific, respectively.

Osiris Therapeutics, Inc. (US), Organogenesis Inc. (US), Vericel Corporation (US), NuVasive, Inc. (US), Stryker Corporation (US), Medtronic (Ireland), Integra LifeSciences (US), Acelity (KCI Concepts) (US), Cook Biotech Inc. (US), RTI surgical (US), C.R. Bard (US), Baxter International, Inc. (US), CryoLife (US), Advanced Cell Technology (US), Sanofi (France), StemCells Inc. (US), BioMimetic Therapeutics (US), and LifeCell Kinetic Concepts (US), are some of the major players operating in the regenerative medicine market.

Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global regenerative medicine market adopt to gain a larger competitive advantage.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

1.1.1 MARKET SYNOPSIS

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY

2.2 RESEARCH OBJECTIVE

2.3 LIST OF ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA MINING

3.3 SECONDARY RESEARCH

3.4 PRIMARY RESEARCH

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES AND GENETIC DISORDERS

4.2.2 GROWING ADOPTION OF STEM CELL TECHNOLOGY

4.2.3 RISING PRODUCT PIPELINE OF REGENERATIVE MEDICINE

4.3 RESTRAINT

4.3.1 ETHICAL CONCERNS FOR THE USE OF EMBRYONIC STEM CELLS

4.4 OPPORTUNITY

4.4.1 IMPLICIT GUIDELINES BY THE INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH (ISSCR) RELATED TO THE EXTENDED EMBRYO CULTURE

4.5 COVID-19 IMPACT ANALYSIS

4.5.1 IMPACT ON MARKET PLAYERS

4.5.2 BRANDED AND GENERIC DRUGS IMPACT ANALYSIS

4.5.3 R&D IMPACT ANALYSIS

4.5.4 FDA POLICIES

4.5.5 OPPORTUNITY ANALYSIS

4.6 PIPELINE ANALYSIS: GLOBAL REGENERATIVE MEDICINE MARKET

5 MARKET FACTOR ANALYSIS

5.1 SUPPLY CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION AND SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

6 GLOBAL REGENERATIVE MEDICINE MARKET, BY TYPE

6.1 OVERVIEW

6.2 CELL THERAPY

6.3 GENE THERAPY

6.4 TISSUE ENGINEERING

6.5 SMALL MOLECULE & BIOLOGIC

7 GLOBAL REGENERATIVE MEDICINE MARKET, BY MATERIAL

7.1 OVERVIEW

7.2 SYNTHETIC

7.3 GENETICALLY ENGINEERED

7.4 BIOLOGICALLY DERIVED

7.5 OTHERS

8 GLOBAL REGENERATIVE MEDICINE MARKET, BY APPLICATION

8.1 OVERVIEW

8.2 MUSCULOSKELETAL DISORDERS

8.3 WOUND CARE

8.4 ONCOLOGY

8.5 OCULAR DISORDERS

8.6 DIABETES

8.7 OTHERS

9 GLOBAL REGENERATIVE MEDICINE MARKET, BY END USER

9.1 OVERVIEW

9.2 HOSPITALS

9.3 SPECIALTY CENTERS

9.4 ACADEMIC & RESEARCH INSTITUTES

9.5 OTHERS

10 GLOBAL REGENERATIVE MEDICINE MARKET, BY REGION

10.1 OVERVIEW

10.2 AMERICAS

10.2.1 NORTH AMERICA

10.2.1.1 U.S

10.2.1.2 CANADA

10.2.2 LATIN AMERICA

10.3 EUROPE

10.3.1 WESTERN EUROPE

10.3.1.1 GERMANY

10.3.1.2 FRANCE

10.3.1.3 UK

10.3.1.4 ITALY

10.3.1.5 SPAIN

10.3.1.6 REST OF WESTERN EUROPE

10.3.2 EASTERN EUROPE

10.4 ASIA PACIFIC

10.4.1 CHINA

10.4.2 INDIA

10.4.3 JAPAN

10.4.4 AUSTRALIA

10.4.5 SOUTH KOREA

10.4.6 REST OF ASIA PACIFIC

10.5 MIDDLE EAST & AFRICA

10.5.1 MIDDLE EAST

10.5.2 AFRICA

11 COMPETITIVE LANDSCAPE

11.1 COMPETITIVEOVERVIEW

11.2 COMPETITOR DASHBOARD

11.3 MAJOR PLAYERS IN THE GLOBAL REGENERATIVE MEDICINE MARKET

11.4 MAJOR GROWTH STRATEGIES IN THE GLOBAL REGENERATIVE MEDICINE MARKET

11.5 COMPETITIVE BENCHMARKING

11.6 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL REGENERATIVE MEDICINE MARKET

11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES

11.7.1 NEW PRODUCT DEVELOPMENTS/LAUNCHES

11.7.2 COLLABORATIONS/ EXPANSIONS/PARTNERSHIPS/JOINT VENTURES

11.8 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO

11.8.1 SALES & OPERATING INCOME

11.8.2 R&D EXPENDITURE

12 COMPANY PROFILES

12.1 ZIMMER BIOMET HOLDINGS INC.

12.1.1 COMPANY OVERVIEWS

12.1.2 FINANCIAL OVERVIEW

12.1.3 PRODUCTS/SERVICES OFFERED

12.1.4 KEY DEVELOPMENTS

12.1.5 SWOT ANALYSIS

12.1.6 KEY STRATEGIES

12.2 ABBVIE INC.

12.2.1 COMPANY OVERVIEW

12.2.2 FINANCIAL OVERVIEW

12.2.3 PRODUCTS/SERVICES OFFERED

12.2.4 KEY DEVELOPMENTS

12.2.5 SWOT ANALYSIS

12.2.6 KEY STRATEGIES

12.3 CRYOLIFE, INC.

12.3.1 COMPANY OVERVIEW

12.3.2 FINANCIAL OVERVIEW

12.3.3 PRODUCTS/SERVICES OFFERED

12.3.4 KEY DEVELOPMENTS

12.3.5 SWOT ANALYSIS

12.3.6 KEY STRATEGIES

12.4 STRYKER

12.4.1 COMPANY OVERVIEW

12.4.2 FINANCIAL OVERVIEW

12.4.3 PRODUCTS/SERVICES OFFERED

12.4.4 KEY DEVELOPMENTS

12.4.5 SWOT ANALYSIS

12.4.6 KEY STRATEGIES

12.5 MEDTRONIC PLC

12.5.1 COMPANY OVERVIEW

12.5.2 FINANCIAL OVERVIEW

12.5.3 PRODUCTS/SERVICES OFFERED

12.5.4 KEY DEVELOPMENTS

12.5.5 SWOT ANALYSIS

12.5.6 KEY STRATEGIES

12.6 BAXTER INTERNATIONAL INC.

12.6.1 COMPANY OVERVIEW

12.6.2 FINANCIAL OVERVIEW

12.6.3 PRODUCTS OFFERED

12.6.4 KEY DEVELOPMENTS

12.6.5 SWOT ANALYSIS

12.6.6 KEY STRATEGIES

12.7 ORGANOGENESIS INC.

12.7.1 COMPANY OVERVIEW

12.7.2 FINANCIAL OVERVIEW

12.7.3 PRODUCTS/SERVICES OFFERED

12.7.4 KEY DEVELOPMENTS

12.7.5 SWOT ANALYSIS

12.7.6 KEY STRATEGIES

12.8 OCATA THERAPEUTICS INC.

12.8.1 COMPANY OVERVIEW

12.8.4 KEY DEVELOPMENTS

12.9 INTEGRA LIFESCIENCES HOLDINGS CORPORATION

12.9.1 COMPANY OVERVIEW

12.9.2 FINANCIAL OVERVIEW

12.9.3 PRODUCTS OFFERED

12.9.4 KEY DEVELOPMENTS

12.9.5 SWOT ANALYSIS

12.9.6 KEY STRATEGIES

12.10 VERICEL CORPORATION

12.10.1 COMPANY OVERVIEW

12.10.2 FINANCIAL OVERVIEW

12.10.3 PRODUCTS OFFERED

12.10.4 KEY DEVELOPMENTS

12.10.5 SWOT ANALYSIS

12.10.6 KEY STRATEGIES

12.11 RELIANCE LIFE SCIENCES

12.11.1 COMPANY OVERVIEW

12.11.2 FINANCIAL OVERVIEW

12.11.3 PRODUCTS/SERVICES OFFERED

12.11.4 KEY DEVELOPMENTS

12.11.5 SWOT ANALYSIS

12.11.6 KEY STRATEGIES


LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 PIPELINE ANALYSIS: GLOBAL REGENERATIVE MEDICINE MARKET

TABLE 3 GLOBAL: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 4 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR CELL THERAPY, BY REGION, 2017–2027 (USD MILLION)

TABLE 5 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 6 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR GENE THERAPY, BY REGION, 2017–2027 (USD MILLION)

TABLE 7 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR TISSUE ENGINEERING, BY REGION, 2017–2027 (USD MILLION)

TABLE 8 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR SMALL MOLECULE & BIOLOGIC, BY REGION, 2017–2027 (USD MILLION)

TABLE 9 GLOBAL: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 10 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR SYNTHETIC, BY REGION, 2017–2027 (USD MILLION)

TABLE 11 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR GENETICALLY ENGINEERED, BY REGION, 2017–2027 (USD MILLION)

TABLE 12 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR BIOLOGICALLY DERIVED, BY REGION, 2017–2027 (USD MILLION)

TABLE 13 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR OTHERS, BY REGION, 2017–2027 (USD MILLION)

TABLE 14 GLOBAL: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 15 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2017–2027 (USD MILLION)

TABLE 16 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR WOUND CARE, BY REGION, 2017–2027 (USD MILLION)

TABLE 17 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR ONCOLOGY, BY REGION, 2017–2027 (USD MILLION)

TABLE 18 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR OCULAR DISORDERS, BY REGION, 2017–2027 (USD MILLION)

TABLE 19 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR DIABETES, BY REGION, 2017–2027 (USD MILLION)

TABLE 20 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR OTHERS, BY REGION, 2017–2027 (USD MILLION)

TABLE 21 GLOBAL: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 22 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR HOSPITALS, BY REGION, 2017–2027 (USD MILLION)

TABLE 23 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR SPECIALTY CENTERS, BY REGION, 2017–2027 (USD MILLION)

TABLE 24 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2017–2027 (USD MILLION)

TABLE 25 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR OTHERS, BY REGION, 2017–2027 (USD MILLION)

TABLE 26 GLOBAL: REGENERATIVE MEDICINE MARKET, BY REGION, 2017–2027 (USD MILLION)

TABLE 27 AMERICAS: REGENERATIVE MEDICINE MARKET, BY REGION, 2017–2027 (USD MILLION)

TABLE 28 AMERICAS: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 29 AMERICAS: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 30 AMERICAS: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 31 AMERICAS: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 32 AMERICAS: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 33 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2017–2027 (USD MILLION)

TABLE 34 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 35 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 36 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 37 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 38 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 39 US: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 40 US: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 41 US: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 42 US: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 43 US: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 44 CANADA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 45 CANADA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 46 CANADA: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 47 CANADA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 48 CANADA: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 49 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 50 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 51 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 52 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 53 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 54 EUROPE: REGENERATIVE MEDICINE MARKET, BY REGION, 2017–2027 (USD MILLION)

TABLE 55 EUROPE: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 56 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 57 EUROPE: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 58 EUROPE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 59 EUROPE: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 60 WESTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2017–2027 (USD MILLION)

TABLE 61 WESTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 62 WESTERN EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 63 WESTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 64 WESTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 65 WESTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 66 GERMANY: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 67 GERMANY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 68 GERMANY: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 69 GERMANY: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 70 GERMANY: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 71 FRANCE: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 72 FRANCE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 73 FRANCE: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 74 FRANCE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 75 FRANCE: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 76 UK: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 77 UK: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 78 UK: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 79 UK: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 80 UK: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 81 ITALY: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 82 ITALY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 83 ITALY: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 84 ITALY: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 85 ITALY: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 86 SPAIN: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 87 SPAIN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 88 SPAIN: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 89 SPAIN: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 90 SPAIN: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 91 REST OF WESTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 92 REST OF WESTERN EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 93 REST OF WESTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 94 REST OF WESTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 95 REST OF WESTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 96 EASTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 97 EASTERN EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 98 EASTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 99 EASTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 100 EASTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 101 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2017–2027 (USD MILLION)

TABLE 102 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 103 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 104 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 105 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 106 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 107 CHINA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 108 CHINA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 109 CHINA: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 110 CHINA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 111 CHINA: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 112 INDIA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 113 INDIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 114 INDIA: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 115 INDIA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 116 INDIA: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 117 JAPAN: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 118 JAPAN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 119 JAPAN: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 120 JAPAN: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 121 JAPAN: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 122 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 123 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 124 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 125 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 126 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 127 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 128 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 129 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 130 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 131 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 132 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 133 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 134 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 135 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 136 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 137 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET, BY REGION, 2017–2027 (USD MILLION)

TABLE 138 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 139 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 140 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 141 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 142 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 143 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 144 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 145 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 146 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 147 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 148 AFRICA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)

TABLE 149 AFRICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)

TABLE 150 AFRICA: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)

TABLE 151 AFRICA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 152 AFRICA: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 153 MAJOR PLAYERS IN THE GLOBAL REGENERATIVE MEDICINE MARKET

TABLE 154 THE MOST ACTIVE PLAYERS IN THE GLOBAL REGENERATIVE MEDICINE MARKET

TABLE 155 NEW PRODUCT DEVELOPMENTS/LAUNCHES

TABLE 156 COLLABORATIONS/EXPANSIONS/PARTNERSHIPS/JOINT VENTURES

TABLE 157 MAJOR PLAYERS R&D EXPENDITURE 2020

TABLE 158 ZIMMER BIOMET HOLDINGS INC.: PRODUCTS/SERVICES OFFERED

TABLE 159 ZIMMER BIOMET HOLDINGS INC.: KEY DEVELOPMENTS

TABLE 160 ABBVIE INC.: PRODUCTS/SERVICES OFFERED

TABLE 161 ABBVIE INC.: KEY DEVELOPMENTS

TABLE 162 CRYOLIFE, INC.: PRODUCTS/SERVICES OFFERED

TABLE 163 STRYKER: PRODUCTS/SERVICES OFFERED

TABLE 164 STRYKER: KEY DEVELOPMENTS

TABLE 165 MEDTRONIC PLC: PRODUCTS/SERVICES OFFERED

TABLE 166 BAXTER INTERNATIONAL INC.: PRODUCTS OFFERED

TABLE 167 ORGANOGENESIS INC.: PRODUCTS/SERVICES OFFERED

TABLE 168 ORGANOGENESIS INC.: KEY DEVELOPMENTS

TABLE 169 OCATA THERAPEUTICS INC.: PRODUCTS/SERVICES OFFERED

TABLE 170 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCTS OFFERED

TABLE 171 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY DEVELOPMENTS

TABLE 172 VERICEL CORPORATION: PRODUCTS OFFERED

TABLE 173 VERICEL CORPORATION: KEY DEVELOPMENTS

TABLE 174 RELIANCE LIFE SCIENCES: PRODUCTS/SERVICES OFFERED

LIST OF FIGURES

FIGURE 1 GLOBAL REGENERATIVE MEDICINE MARKET STRUCTURE

FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES

FIGURE 3 MARKET DYNAMICS: REGENERATIVE MEDICINE MARKET

FIGURE 4 DRIVERS: IMPACT ANALYSIS

FIGURE 5 RESTRAINT: IMPACT ANALYSIS

FIGURE 6 SUPPLY CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET

FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL REGENERATIVE MEDICINE MARKET

FIGURE 8 GLOBAL REGENERATIVE MEDICINE MARKET, BY TYPE, 2020 & 2027 (USD MILLION)

FIGURE 9 GLOBAL: REGENERATIVE MEDICINE MARKET, MATERIAL 2020 & 2027 (USD MILLION)

FIGURE 10 GLOBAL: REGENERATIVE MEDICINE MARKET, APPLICATION, 2020 & 2027 (USD MILLION)

FIGURE 11 GLOBAL: REGENERATIVE MEDICINE MARKET, END USER, 2020 & 2027 (USD MILLION)

FIGURE 12 GLOBAL: REGENERATIVE MEDICINE MARKET, BY REGION 2020 & 2027 (USD MILLION)

FIGURE 13 GLOBAL: REGENERATIVE MEDICINE MARKET SHARE, BY REGION 2020 (%)

FIGURE 14 AMERICAS: REGENERATIVE MEDICINE MARKET SHARE, BY REGION 2020 (%)

FIGURE 15 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SHARE, BY COUNTRY 2020 (%)

FIGURE 16 EUROPE: REGENERATIVE MEDICINE MARKET SHARE, BY REGION 2020 (%)

FIGURE 17 WESTERN EUROPE: REGENERATIVE MEDICINE MARKET SHARE, BY COUNTRY 2020 (%)

FIGURE 18 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SHARE, BY COUNTRY 2020 (%)

FIGURE 19 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET SHARE, BY REGION 2020 (%)

FIGURE 20 COMPETITOR DASHBOARD: GLOBAL REGENERATIVE MEDICINE MARKET

FIGURE 21 CONTRACTS & AGREEMENTS: THE MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL REGENERATIVE MEDICINE MARKET

FIGURE 22 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 23 SALES & OPERATING INCOME 2020

FIGURE 24 ZIMMER BIOMET HOLDINGS INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 ZIMMER BIOMET HOLDINGS INC.: SWOT ANALYSIS

FIGURE 26 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 ABBVIE INC.: SWOT ANALYSIS

FIGURE 28 CRYOLIFE, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 CRYOLIFE, INC.: SWOT ANALYSIS

FIGURE 30 STRYKER: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 STRYKER: SWOT ANALYSIS

FIGURE 32 MEDTRONIC PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 MEDTRONIC PLC: SWOT ANALYSIS

FIGURE 34 BAXTER INTERNATIONAL INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 BAXTER INTERNATIONAL INC.: SWOT ANALYSIS

FIGURE 36 ORGANOGENESIS INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 37 ORGANOGENESIS INC.: SWOT ANALYSIS

FIGURE 39 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 40 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: SWOT ANALYSIS

FIGURE 41 VERICEL CORPORATION: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 42 VERICEL CORPORATION: SWOT ANALYSIS

FIGURE 43 RELIANCE INDUSTRIES LIMITED: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 44 RELIANCE LIFE SCIENCES: SWOT ANALYSIS



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.